US OptionsDetailed Quotes

MNOV241018C2500

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Oct 3 12:52 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Trytosaveabit
    Trytosaveabit
    Sep 30 21:07
    Update
    $MediciNova (MNOV.US)$ Reuters· 5 mins ago
    MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
    Jaguar8
    Jaguar8
    Sep 30 21:00
    NEWS
    $MediciNova (MNOV.US)$
    MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
    MediciNova (NASDAQ:MNOV) has announced its support for an NIH-funded Expanded Access Protocol (EAP) trial to evaluate MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS). The NIH-NINDS has awarded $22 million for this intermediate-size trial, which will allow 200 ALS patients who are ineligible for the ongoing COMBAT-ALS trial to rec...
    Jaguar8
    Jaguar8
    Sep 10 13:13
    NEWS
    $MediciNova (MNOV.US)$
    MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
    MediciNova, Inc. (NASDAQ:MNOV) has announced that an abstract regarding the COMBAT-ALS clinical trial of MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment has been accepted for poster presentation at the 35th International Symposium on ALS / MND. The symposium will take place from Dec...
    Jaguar8
    Jaguar8
    Aug 30 15:54
    NEWS THUR AH
    $MediciNova (MNOV.US)$
    MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
    MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depre...
    Trytosaveabit
    Trytosaveabit
    Jun 5 18:08
    News
    $MediciNova (MNOV.US)$ Reuters· 2 mins ago
    Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer
Read more